drugset
drugset / Trial / NCT05093855

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05093855 ↗

Phase 2 Completed 41 enrolled Staidson (Beijing) Biopharmaceuticals Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore whether BDB-001 Injection is effective and safe in the treatment of moderate to severe hidradenitis suppurativa(HS).

Timeline

Start
2021-08-18
Primary completion
2023-08-22
Completion
2023-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiquimod Small molecule — Intravenous

Indications

hidradenitis suppurativa